Publications by authors named "Deva Situnayake"

Claim this Profile
P
Predicting response to infliximab and interferon-α in Behçet's syndrome: An exploratory analysis from the BIO-BEHÇET'S randomized controlled trial.
Robert J Moots, Farida Fortune, Richard Jackson, Tony Thornburn, Ann W Morgan, Deva Situnayake

Rheumatol Immunol Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infliximab vs interferon-α in the treatment of Behçet's syndrome: clinical data from the BIO-BEHÇET'S randomized controlled trial.
Robert J Moots, Farida Fortune, Richard Jackson, Tony Thornburn, Ann Morgan, Deva Situnayake

Rheumatology (Oxford)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential for biosimilars to address unmet clinical need - Is the developed world missing out?
Whei Chuern Yeoh, Deva Situnayake, Robert J Moots

Rheumatol Immunol Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recurrent endobronchial occlusion and aorto-bronchial fistula formation in Behcet's disease.
Niloy Rahman, Eshan Senanayake, Jorge Mascaro, Deva Situnayake, Ehab S Bishay

J Cardiothorac Surg· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interrelationships between heath utility measurements, disease activity and psychological factors in Behçet's disease.
Philip I Murray, Anisha Sekaran, Hedayat Javidi, Deva Situnayake

Gen Hosp Psychiatry· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology, morbidity and mortality in Behçet's disease: a cohort study using The Health Improvement Network (THIN).
Tom Thomas, Joht Singh Chandan, Anuradhaa Subramanian, Krishna Gokhale, George Gkoutos, Deva Situnayake

Rheumatology (Oxford)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Behçet's centres of excellence.
Robert J Moots, Farida Fortune, Deva Situnayake

Rheumatology (Oxford)· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Birmingham Behçet's service: classification of disease and application of the 2014 International Criteria for Behçet's Disease (ICBD) to a UK cohort.
Tim Blake, Luke Pickup, David Carruthers, Erika Marie Damato, Alastair Denniston, Deva Situnayake

BMC Musculoskelet Disord· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetics of Behçet's disease.
Laura T Morton, Deva Situnayake, Graham R Wallace

Curr Opin Rheumatol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years.
Chee-Seng Yee, Li Su, Veronica Toescu, Richard Hickman, Deva Situnayake

Rheumatology (Oxford)· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment of calcinosis with infliximab in a patient with systemic sclerosis/myositis overlap syndrome.
Sofia Tosounidou, Hannah MacDonald, Deva Situnayake

Rheumatology (Oxford)· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease.
Imran J Khan, Robert J Barry, Kwesi N Amissah-Arthur, David Carruthers, Srinivasa Rao Elamanchi, Deva Situnayake

Br J Ophthalmol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Refractory multisystem sarcoidosis responding to infliximab therapy.
Adam P Croft, Deva Situnayake, Omer Khair, Gavin Giovanni, David Carruthers

Clin Rheumatol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breaking communication barriers for RA patients of South Asian origin: the use of a bilingual educational audio CD and linguistically appropriate peer support and education.
Kanta Kumar, Holly John, Chandrika Gordhan, Deva Situnayake, Karim Raza

Musculoskeletal Care· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
Bridget Griffiths, Paul Emery, Vicky Ryan, David Isenberg, Mohammed Akil, Deva Situnayake

Rheumatology (Oxford)· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B.
Ann W Morgan, Jennifer H Barrett, Bridget Griffiths, Deepak Subramanian, Jim I Robinson, R Deva Situnayake

Arthritis Res Ther· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis.
Karim Raza, Mike Breese, Peter Nightingale, Kanta Kumar, Tanya Potter, Deva Situnayake

J Rheumatol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lupus and zoster.
Karen M J Douglas, Caroline Gordon, Husam Osman, Stephanie Heaton, Jan Skan, Deva Situnayake

Lancet· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis